Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 071.35 INR 1.39% Market Closed
Market Cap: 944.3B INR
Have any thoughts about
Lupin Ltd?
Write Note

Intrinsic Value

The intrinsic value of one LUPIN stock under the Base Case scenario is 1 418.64 INR. Compared to the current market price of 2 071.35 INR, Lupin Ltd is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LUPIN Intrinsic Value
1 418.64 INR
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lupin Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LUPIN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LUPIN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Lupin Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Lupin Ltd

Provide an overview of the primary business activities
of Lupin Ltd.

What unique competitive advantages
does Lupin Ltd hold over its rivals?

What risks and challenges
does Lupin Ltd face in the near future?

Has there been any significant insider trading activity
in Lupin Ltd recently?

Summarize the latest earnings call
of Lupin Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lupin Ltd.

Provide P/S
for Lupin Ltd.

Provide P/E
for Lupin Ltd.

Provide P/OCF
for Lupin Ltd.

Provide P/FCFE
for Lupin Ltd.

Provide P/B
for Lupin Ltd.

Provide EV/S
for Lupin Ltd.

Provide EV/GP
for Lupin Ltd.

Provide EV/EBITDA
for Lupin Ltd.

Provide EV/EBIT
for Lupin Ltd.

Provide EV/OCF
for Lupin Ltd.

Provide EV/FCFF
for Lupin Ltd.

Provide EV/IC
for Lupin Ltd.

Show me price targets
for Lupin Ltd made by professional analysts.

What are the Revenue projections
for Lupin Ltd?

How accurate were the past Revenue estimates
for Lupin Ltd?

What are the Net Income projections
for Lupin Ltd?

How accurate were the past Net Income estimates
for Lupin Ltd?

What are the EPS projections
for Lupin Ltd?

How accurate were the past EPS estimates
for Lupin Ltd?

What are the EBIT projections
for Lupin Ltd?

How accurate were the past EBIT estimates
for Lupin Ltd?

Compare the revenue forecasts
for Lupin Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lupin Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lupin Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lupin Ltd compared to its peers.

Compare the P/E ratios
of Lupin Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Lupin Ltd with its peers.

Analyze the financial leverage
of Lupin Ltd compared to its main competitors.

Show all profitability ratios
for Lupin Ltd.

Provide ROE
for Lupin Ltd.

Provide ROA
for Lupin Ltd.

Provide ROIC
for Lupin Ltd.

Provide ROCE
for Lupin Ltd.

Provide Gross Margin
for Lupin Ltd.

Provide Operating Margin
for Lupin Ltd.

Provide Net Margin
for Lupin Ltd.

Provide FCF Margin
for Lupin Ltd.

Show all solvency ratios
for Lupin Ltd.

Provide D/E Ratio
for Lupin Ltd.

Provide D/A Ratio
for Lupin Ltd.

Provide Interest Coverage Ratio
for Lupin Ltd.

Provide Altman Z-Score Ratio
for Lupin Ltd.

Provide Quick Ratio
for Lupin Ltd.

Provide Current Ratio
for Lupin Ltd.

Provide Cash Ratio
for Lupin Ltd.

What is the historical Revenue growth
over the last 5 years for Lupin Ltd?

What is the historical Net Income growth
over the last 5 years for Lupin Ltd?

What is the current Free Cash Flow
of Lupin Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lupin Ltd.

Business Breakdown

Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lupin Ltd

Current Assets 134.5B
Cash & Short-Term Investments 25.3B
Receivables 59.3B
Other Current Assets 49.9B
Non-Current Assets 105.5B
Long-Term Investments 2.3B
PP&E 54.9B
Intangibles 41.6B
Other Non-Current Assets 6.7B
Current Liabilities 85B
Accounts Payable 29.6B
Accrued Liabilities 4.2B
Short-Term Debt 26.7B
Other Current Liabilities 24.5B
Non-Current Liabilities 12.1B
Long-Term Debt 1.6B
Other Non-Current Liabilities 10.5B
Efficiency

Earnings Waterfall
Lupin Ltd

Revenue
208B INR
Cost of Revenue
-67.4B INR
Gross Profit
140.5B INR
Operating Expenses
-110.3B INR
Operating Income
30.2B INR
Other Expenses
-7.6B INR
Net Income
22.6B INR

Free Cash Flow Analysis
Lupin Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Lupin delivered impressive Q2 FY '25 results, with sales rising 11.3% year-on-year to INR 5,497 crores and a 13.7% increase for H1. In India, revenues surged by 19%, significantly outperforming market growth. The U.S. business saw a 3% revenue increase, supported by the launch of new products like Mirabegron. The company projects close to double-digit revenue growth in the U.S. for the fiscal year, targeting EBITDA margins between 22% and 23%. Additionally, a robust product pipeline in complex generics is set to enhance profitability moving forward.

What is Earnings Call?
Fundamental Scores

LUPIN Profitability Score
Profitability Due Diligence

Lupin Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
55/100
Profitability
Score

Lupin Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

LUPIN Solvency Score
Solvency Due Diligence

Lupin Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
71/100
Solvency
Score

Lupin Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LUPIN Price Targets Summary
Lupin Ltd

Wall Street analysts forecast LUPIN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LUPIN is 2 208.36 INR with a low forecast of 973.64 INR and a high forecast of 2 887.5 INR.

Lowest
Price Target
973.64 INR
53% Downside
Average
Price Target
2 208.36 INR
7% Upside
Highest
Price Target
2 887.5 INR
39% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LUPIN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for LUPIN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

LUPIN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Lupin Ltd Logo
Lupin Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

943.9B INR

Dividend Yield

0.39%

Description

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 19,789 full-time employees. The firm develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. The company offers vitamins, minerals, supplements and neurological products. The company has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. The company supplies APIs for anti-retroviral, anti-malarial and others.

Contact

MAHARASHTRA
Mumbai
Laxmi Towers, 'B' Wing,, Bandra Kurla Complex,, Bandra (East),
+912266402222
www.lupin.com

IPO

1994-11-30

Employees

19 789

Officers

CEO & Executive Director
Ms. Vinita D. Gupta
Executive Director, Global CFO, CRO & Head of API Plus SBU
Mr. Ramesh Swaminathan
MD & Executive Director
Mr. Nilesh Deshbandhu Gupta
Chief Technical Operations Officer
Mr. Christoph Funke
Chief Information Officer
Mr. Sreeji Gopinathan
Global Chief Scientific Officer
Dr. Shahin Fesharaki
Show More
Sr. Vice President of Investor Relations and M&A
Mr. Ravi Agrawal
President of Legal and Compliance of Australia, Japan & Canada Business
Dr. Sofia Mumtaz
Company Secretary & Compliance Officer
Mr. Amit Kumar Gupta
Vice President & Global Head of Corporate Communications
Ms. Rajalakshmi Azariah
Show Less

See Also

Discover More
What is the Intrinsic Value of one LUPIN stock?

The intrinsic value of one LUPIN stock under the Base Case scenario is 1 418.64 INR.

Is LUPIN stock undervalued or overvalued?

Compared to the current market price of 2 071.35 INR, Lupin Ltd is Overvalued by 32%.

Back to Top